Jefferies Group Raises Infinity Pharmaceuticals Price Target to $18.00 (INFI)
Equities research analysts at Jefferies Group upped their target price on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $13.00 to $18.00 in a research note issued to investors on Thursday. Jefferies Group’s price target suggests a potential upside of 14.31% from the stock’s previous close.
Infinity Pharmaceuticals (NASDAQ:INFI) traded down 7.50% on Thursday, hitting $14.55. The stock had a trading volume of 3,328,749 shares. Infinity Pharmaceuticals has a one year low of $8.40 and a one year high of $21.60. The stock’s 50-day moving average is $10.58 and its 200-day moving average is $11.34. The company’s market cap is $706.9 million. Infinity Pharmaceuticals also saw unusually large options trading on Wednesday. Investors bought 10,671 put options on the company. This is an increase of 1,206% compared to the average volume of 817 put options.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Tuesday, August 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.06. During the same quarter in the previous year, the company posted ($0.68) earnings per share. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Infinity Pharmaceuticals will post $-3.48 earnings per share for the current fiscal year.
INFI has been the subject of a number of other recent research reports. Analysts at JMP Securities upgraded shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday. They now have a $24.00 price target on the stock. Separately, analysts at Roth Capital reiterated a “positive” rating on shares of Infinity Pharmaceuticals in a research note on Wednesday. Finally, analysts at Wedbush upgraded shares of Infinity Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Wednesday. They now have a $15.00 price target on the stock, up previously from $9.00. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $18.67.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Receive News & Ratings for Infinity Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.